Experimental approaches in personalised medicine in urothelium tumours
Poster Session 39
-
Location:Room Madrid, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session The course of bladder cancer could be affected by many factors. In order to predict the course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1Saarland University Medical Center, Dept. of Urology, Homburg, Germany, 2Saarland University Medical Center, Dept. of Physiology, Homburg, Germany, 3University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark
Institutes: 1Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, 2MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China
Institutes: 1The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan, 2Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, 3Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan, 4The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan, 5Toranomon Hospital, Dept. of Urology, Minato, Japan, 6Nagoya Medical Center, Advanced Diagnosis, Clinical Reserach Center, Nagoya, Japan
Institutes: 1Translational Medicine, Dept. of Urologic Research, Lund, Sweden, 2Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden
Institutes: 1Hospital Clinic, IDIBAPS, Dept. of Urology, Barcelona, Spain, 2Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 3Hospital Clinic, CIBERehd, IDIBAPS, Barcelona, Spain, 4Radboudumc, Dept. of Experimental Urology, Nijmegen, The Netherlands, 5Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, 6MD Anderson Cancer Center, Dept. of Urology, Houston, Texas, United States of America, 7MD Anderson Cancer Center, Dept. of Pathology, Houston, Texas, United States of America, 8Radboudumc, Dept. of Health Evidence, Nijmegen, The Netherlands
Institutes: 1Turku University Hospital, Dept. of Urology, Turku, Finland, 2University of Turku, Institution of Biotechnology, Turku, Finland, 3Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, 4Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUSLAB), Helsinki, Finland, 5Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 6Turku University Hospital, Dept. of Pathology, Turku, Finland
Institutes: 1Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, 2Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, 3Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan
Institutes: 1University of Regensburg, Dept. of Urology, Regensburg, Germany, 2Stratifyer Molecular Pathology GmbH, Cologne, Germany, 3University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 4University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany
Institutes: 1Shandong University, School of Nursing, Jinan, China, 2Shandong University Qilu Hospital, Dept. of Urology, Jinan, China
Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of Bern, Dept. of Urology, Bern, Switzerland, 3University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 4University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, 5University of Bern, Institute of Pathology, Bern, Switzerland, 6Hiroshima University, Dept. of Urology, Hiroshima, Japan, 7GenomeDx, Biosciences, Vancouver, Canada